Current stock page

Stock Analysis

Pacific Biosciences of California, Inc. (PACB) Stock Analysis

Pacific Biosciences of California, Inc. (PACB) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

PACB Stock Analysis Summary

Pacific Biosciences of California, Inc. (PACB) currently has an AIQ Score of 48/100, indicating a bearish setup. Momentum is the strongest factor at 84/100. Value is the weakest current factor at 23/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 18, 2026 · Market-close data

PACB at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$1.83
AIQ Score48/100
Overall ViewBearish
Technical Analysis ConsensusSell
Market Cap$610.04M
P/E Ratio (TTM)-4.33
Forward P/E—
EPS (Q3 FY2026)-$0.12
Revenue (Q3 FY2026)$40.56M
Dividend Yield (TTM)0.00%
Beta2.1
Volume15.32M
52-week range$1.07-$3.44
RSI 1443.07
50-Day SMA$2.00
200-Day SMA$1.60
Analyst Price Target$1.93
Next EarningsFeb 9, 2027
As of Nov 18, 2026 · Market close

PACBPacific Biosciences of California, Inc.

Healthcare / Medical - Devices

Low Priority

In Line With Peers

BearishEdge 4/10
$1.83+$0.01 (+0.55%)

Latest quote

  • Momentum
    84
  • Value
    23
  • Quality
    32
  • Risk resilience
    24
  • Sentiment
    —
algovestiq.comScore data as of Nov 18, 2026

PACB Stock Analysis Summary

Pacific Biosciences of California, Inc. (PACB) currently has an AIQ Score of 48/100, indicating a bearish setup. Momentum is the strongest factor at 84/100. Value is the weakest current factor at 23/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 18, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, PACB has AIQ Score of 48/100 with Momentum base of 84/100 and fading Value at 23/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (84/100) leads while Value (23/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 0.55% stock move · PACB classified in Medical - Devices.

Current Evidence

BearishPACB is in a bearish AIQ regime; Momentum is the strongest visible factor at 84/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is PACB Bullish or Bearish Right Now?

PACB currently has a bearish overall setup. Momentum is the strongest factor at 84/100, while Value is weakest at 23/100. The current evidence suggests a bearish setup.

Bull Case
  • - Momentum is constructive at 84/100.
  • - Analyst target implies +5.19% upside from the latest quote.
Bear Case
  • - Value is the current constraint at 23/100.
  • - Risk Resilience is weak at 24/100.
  • - Technical consensus has more sell votes than buy votes (27 vs 15).

Current Consensus

PACB's Technical Analysis Consensus is currently Sell, with 15 buy, 4 neutral, and 27 sell votes. PACB's 14-day RSI is 43.07, which places the stock in a weaker momentum range. PACB's beta is 2.1, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in PACB?

The largest recent change in PACB is Quality moving down by 3.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
-2.0
Momentum
-1.0
Quality
-3.0
Risk
+1.0

What Would Change the PACB Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

PACB Decision Framework

Public evidence layers, setup checks, and risk context for Pacific Biosciences of California, Inc..

Pacific Biosciences of California, Inc. (PACB) Stock Analysis

Pacific Biosciences of California, Inc. has an AIQ Score of 48/100 in a Bearish regime. Momentum is strongest at 84/100. Beta is 2.1, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextPACB is in a Bearish AIQ regime with score 48/100.
Signal ConflictThe primary conflict is that momentum leads at 84/100 while value lags at 23/100.
Factor EvidenceMomentum 84/100 · Value 23/100 · Quality 32/100 · Risk 24/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 84/100.

TimingPass

Momentum is 84/100 and RSI (14) is 43.1.

Regime fitFail

PACB is in a Bearish regime at 48/100.

Risk controlFail

Risk factor is 24/100 with beta 2.1 and annual volatility 93.55%.

ConflictWait

Current conflict: momentum leads at 84/100 while value lags at 23/100.

AIQ Score
48/100
Price
$1.83
Beta
2.1
RSI (14)
43.1

PACB Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

PACB Fundamentals

PACB valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$40.56M
Net income
-$37.85M
Free cash flow
-$38.59M
View full PACB fundamental analysis

PACB Technical Analysis

PACB technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Sell
RSI 14
43.07
Price vs SMA-50
-2.24%
View full PACB technical analysis

PACB Stock Catalysts

Track PACB earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 9, 2027
Analyst target
$1.93
News items
2
View PACB earnings and stock catalysts

PACB Dividend Analysis

PACB dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View PACB dividend history and analysis

PACB Financial Data

PACB revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$40.56M
EPS
-$0.12
Periods
8
View PACB financials

PACB Risk Analysis

PACB volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
2.1
Risk score
24/100
1Y volatility
93.55%
View PACB risk analysis

PACB Stock News

PACB stock news, market tone, recent headlines, and catalyst context.

News items
2
Updated
Nov 18, 2026
Sentiment
—
Read PACB stock news

PACB vs Medical - Devices Peers

Current peer cohort: PACB · PEN · PHG · PRCT · SNN. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
PACB
Current stock
48/10023/10084/10024/1000.6193.55%Current
PEN
Penumbra, Inc.
66/10048/10056/10092/1000.6219.46%PACB vs PEN
PHG
Koninklijke Philips N.V.
72/10080/10072/10073/1000.1829.69%PACB vs PHG
PRCT
PROCEPT BioRobotics Corporation
49/10038/10060/10045/100-0.1165.89%PACB vs PRCT
SNN
Smith & Nephew plc
70/10079/10060/10075/100-0.227.30%PACB vs SNN
Pairwise Compare links: PEN · PHG · PRCT · SNNPACB vs PENPACB vs PHGPACB vs PRCTPACB vs SNNCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 18, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 18, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a PACB stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for PACB: historical return with reinvested dividends, dollar-cost averaging (DCA) backtest and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 19, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-4.33
As of Nov 18, 2026
Revenue growth
5.52%
Gross margin
34.51%
Current debt / equity
-11.49
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$40.56M
Quarter net income
-$37.85M
Quarter free cash flow
-$38.59M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bearish
RSI 14
43.07
MACD
0.02

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
24/100
Beta
2.1
Annual volatility
93.55%
Max drawdown
-58.43%

PACB Stock FAQ

What is PACB stock price today?

Pacific Biosciences of California, Inc.'s current stock price is $1.83. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is PACB bullish or bearish right now?

PACB's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is PACB's market cap?

PACB's market cap is $610.04M based on the latest completed market-close snapshot from Nov 18, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is PACB's current P/E ratio?

PACB's current P/E ratio is -4.33 based on the latest completed market-close snapshot from Nov 18, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is PACB's RSI?

PACB's 14-day RSI is 43.07 based on the latest completed market-close snapshot from Nov 18, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is PACB above its 50-day and 200-day moving averages?

PACB is -2.24% from its 50-day SMA and 22.41% from its 200-day SMA based on the latest completed market-close snapshot from Nov 18, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is PACB's next earnings date?

PACB's next earnings date is currently listed as Feb 9, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does PACB pay a dividend?

PACB's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 18, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.